18:0 LPA | 65494-37-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 18:0 LPA
• 英文别名: 1-Stearoyl-sn-glycero-3-phosphate；[(2R)-2-hydroxy-3-phosphonooxypropyl] octadecanoate
• CAS: 65494-37-3
• 化学式: C₂₁H₄₃O₇P
• 分子量: 438.542
• InChiKey: LAYXSTYJRSVXIH-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  29
• 可旋转键数：
  22
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  [1-¹⁴C]-oleoyl CoA 、 18:0 LPA 在 recombinant mouse His₁₂-CGI-58 fusion protein 作用下， 反应 0.17h， 生成
  参考文献：
  名称：

  CGI-58/ABHD5 is a coenzyme A-dependent lysophosphatidic acid acyltransferase

  摘要：

  Mutations in human CGI-58/ABHD5 cause Chanarin-Dorfman syndrome (CDS), characterized by excessive storage of triacylglycerol in tissues. CGI-58 is an alpha/beta-hydrolase fold enzyme expressed in all vertebrates. The carboxyl terminus includes a highly conserved consensus sequence (HXXXXD) for acyltransferase activity. Mouse CGI-58 was expressed in Escherichia coli as a fusion protein with two amino terminal 6-histidine tags. Recombinant CGI-58 displayed acyl-CoA-dependent acyltransferase activity to lysophosphatidic acid, but not to other lysophospholipid or neutral glycerolipid acceptors. Production of phosphatidic acid increased with time and increasing concentrations of recombinant CGI-58 and was optimal between pH 7.0 and 8.5. The enzyme showed saturation kinetics with respect to 1-oleoyl-lysophosphatidic acid and oleoyl-CoA and preference for arachidonoyl-CoA and oleoyl-CoA. The enzyme showed slight preference for 1-oleoyl lysophosphatidic acid over 1-palmitoyl, 1-stearoyl, or 1-arachidonoyl lysophosphatidic acid. Recombinant CGI-58 showed intrinsic fluorescence for tryptophan that was quenched by the addition of 1-oleoyl-lysophosphatidic acid, oleoyl-CoA, arachidonoyl-CoA, and palmitoyl-CoA, but not by lysophosphatidyl choline. Expression of CGI-58 in fibroblasts from humans with CDS increased the incorporation of radiolabeled fatty acids released from the lipolysis of stored triacylglycerols into phospholipids. CGI-58 is a CoA-dependent lysophosphatidic acid acyltransferase that channels fatty acids released from the hydrolysis of stored triacylglycerols into phospholipids.-Montero-Moran, G., J. M. Caviglia, D. McMahon, A. Rothenberg, V. Suramanian, Z. Xu, S. Lara-Gonzalez, J. Storch, G. M. Carman, and D. L. Brasaemle. CGI-58/ABHD5 is a coenzyme A-dependent lysophosphatidic acid acyltransferase. J. Lipid Res. 2010. 51: 709-719.

  DOI：

  10.1194/jlr.m001917

文献信息

• Use of ceramides and LPLs in diagnosing CVD
  申请人：ZORA BIOSCIENCES, OY

  公开号：US10184932B2

  公开（公告）日：2019-01-22

  The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.

  本发明特别提供了一种方法及其用途，通过测定生物样本中至少一种式I神经酰胺或一种式II和/或III溶血磷脂以及至少一种式IV、V、VI、VII和/或VIII溶血磷脂的浓度，并将这些浓度与对照组进行比较，从而预测冠心病事件，如AMI、ACS、中风和冠心病死亡。如果发现至少一种式 I 神经酰胺或式 II 和/或式 III 溶血磷脂的浓度升高，而至少一种式 IV、V、VI、VII 和/或 VIII 溶血磷脂的浓度降低，则表明受试者发生一种或多种心血管事件的风险升高。本公开还提供了一种诊断急性缺血患者的方法及其用途。还提供了包含相同成分的试剂盒和组合物，用于预测和/或诊断 CV 事件。
• Semi-biosynthetic production of fatty alcohols and fatty aldehydes
  申请人：Provivi, Inc.

  公开号：US11214818B2

  公开（公告）日：2022-01-04

  The present application relates to methods of producing one or more fatty alcohols and/or one or more fatty aldehydes from one or more unsaturated lipid moieties by combining the obtainment or production of the one or more unsaturated lipid moieties from a biological source with conversion by non-biological means of the one or more unsaturated lipid moieties to one or more fatty alcohols and/or one or more fatty aldehydes. The present application also relates to recombinant microorganisms having a biosynthesis pathway for the production of one or more unsaturated lipid moieties. The one or more fatty alcohols can further be chemically converted to one or more corresponding fatty acetates. The one or more fatty alcohols, one or more fatty aldehydes and/or one or more fatty acetates produced by the methods described herein may be one or more insect pheromones, one or more fragrances, one or more flavoring agents, or one or more polymer intermediates.

  本申请涉及从一种或多种不饱和脂质分子生产一种或多种脂肪醇和/或一种或多种脂肪醛的方法，方法是将从生物来源获得或生产一种或多种不饱和脂质分子与通过非生物手段将一种或多种不饱和脂质分子转化为一种或多种脂肪醇和/或一种或多种脂肪醛结合起来。本申请还涉及具有生产一种或多种不饱和脂质分子的生物合成途径的重组微生物。一种或多种脂肪醇可进一步化学转化为一种或多种相应的脂肪乙酸酯。本文所述方法生产的一种或多种脂肪醇、一种或多种脂肪醛和/或一种或多种脂肪乙酸酯可以是一种或多种昆虫信息素、一种或多种香料、一种或多种调味剂或一种或多种聚合物中间体。
• MICROORGANISMS FOR THE PRODUCTION OF INSECT PHEROMONES AND RELATED COMPOUNDS
  申请人：Provivi, Inc.

  公开号：EP3635124A1

  公开（公告）日：2020-04-15
• Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions
  申请人：Sabbadini A. Roger

  公开号：US20070148168A1

  公开（公告）日：2007-06-28

  The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).
• Methods for decreasing immune response and treating immune conditions
  申请人：Sabbadini Roger A.

  公开号：US20070280933A1

  公开（公告）日：2007-12-06

  The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which are characterized by an aberrant, excessive or undesired immune response. The methods of the invention utilize agents that bind bioactive lipids and are capable of decreasing the effective concentration of the bioactive lipid. In some embodiments, the agent is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).